scholarly journals Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?

BMC Medicine ◽  
2013 ◽  
Vol 11 (1) ◽  
Author(s):  
Jean-Michel Molina ◽  
Claire Pintado ◽  
Caroline Gatey ◽  
Diane Ponscarme ◽  
Pierre Charbonneau ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Challenges And Opportunities ◽  
Exposure Prophylaxis ◽  
Prevention Of Hiv

scholarly journals The review of pre-exposure prophylaxis (PreP) for HIV prevention

2014 ◽  
Vol 11 (1) ◽  
pp. 50-59
Author(s):  
Meriam Caboral Stevens ◽  
Godfrey Aneke ◽  
Andrew Neplock
Keyword(s):  
Hiv Prevention ◽  
Global Health ◽  
Hiv Infection ◽  
Condom Use ◽  
Biomedical Research ◽  
Prevention Strategies ◽  
Global Health Issue ◽  
Exposure Prophylaxis ◽  
Current Guidelines ◽  
Prevention Of Hiv

Human lmmunodeficiency Virus (HlV) epidemic continues to represent a major global health issue. Today, there are several tools available to prevent the spread of HIV infection. However, there are several constraints to the current prevention strategies including low condom use, low acceptance of testing, low awareness of vulnerability and more emphasis on treatment. Prevention strategy is redirected towards reducing acquisition of HIV. Pre-exposure prophylaxis or PrEP is the latest groundbreaking innovation in biomedical research in the prevention of HIV transmission.The purpose of this paper is to review preex ding the current guidelines in the use of PreP.

Antiretroviral Therapy in Children and Newborns

2017 ◽  
Author(s):  
Karin Nielsen-Saines
Keyword(s):  
Hiv Infection ◽  
Pediatric Hiv ◽  
Post Exposure Prophylaxis ◽  
Older Children ◽  
Viral Reservoirs ◽  
Young Infants ◽  
Exposure Prophylaxis ◽  
Prevention Of Hiv ◽  
Infants And Young Children ◽  
Early Antiretroviral Treatment

HIV-infected infants and children have a different, more progressive disease course compared to that of adults given that early infection leads to sustained, high-magnitude viremia with significant seeding of reservoirs in the first months of life. Early diagnosis of HIV infection is pivotal in the management of infants and prevention of HIV-associated morbidity and mortality. The availability of potent pediatric antiretroviral formulations encompassing different classes of drugs for infected infants and young children is limited. Significant advancements have been achieved in the area of infant post-exposure prophylaxis. Early antiretroviral treatment is still the mainstay of pediatric HIV infection, particularly for infants younger than age 12 months, but it is also highly recommended for older children. Early treatment of young infants diagnosed soon after birth appears to be the best approach to reduce the seeding of viral reservoirs and potentially attain prolonged periods of HIV remission off antiretrovirals.

Unsupervised PrEP in routine practice: a new challenge?

2019 ◽  
Vol 30 (7) ◽  
pp. 715-717
Author(s):  
Hélène Laroche ◽  
Caroline Lions ◽  
Olivia Zaegel-Faucher ◽  
Catherine Tamalet ◽  
Isabelle Poizot-Martin
Keyword(s):  
Viral Load ◽  
Hiv Infection ◽  
Western Blot ◽  
Plasma Viral Load ◽  
Routine Practice ◽  
Substantial Risk ◽  
Sex With Men ◽  
Exposure Prophylaxis ◽  
Prevention Option ◽  
Prevention Of Hiv

Pre-exposure prophylaxis (PrEP) for the prevention of HIV infection with 300 mg daily tenofovir co-formulated with 200 mg emtricitabine is recommended as one prevention option for people who are at substantial risk of acquiring an HIV infection. We report the case of a 28-year-old man who has sex with men and who was referred to our unit for a primary HIV infection with positive p18, p24 and gp160 bands on Western blot analysis but with a low HIV plasma viral load. Although HIV misdiagnosis should always be considered in cases of atypical seroconversion pattern with a low viral burden, unsupervised PrEP should be systematically investigated.

Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016

2017 ◽  
Vol 35 (6) ◽  
pp. 377-383
Author(s):  
Santiago Moreno ◽  
Antonio Antela ◽  
Felipe García ◽  
Julia del Amo ◽  
Vicente Boix ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Executive Summary ◽  
Exposure Prophylaxis ◽  
Prevention Of Hiv

scholarly journals Cost Effectiveness of ‘On Demand’ Hiv Pre-Exposure Prophylaxis for Non-Injection Drug-Using Men Who Have Sex with Men in Canada

2015 ◽  
Vol 26 (1) ◽  
pp. 23-29 ◽  
Author(s):  
Estelle Ouellet ◽  
Madeleine Durand ◽  
Jason R Guertin ◽  
Jacques LeLorier ◽  
Cécile L Tremblay
Keyword(s):  
Cost Effectiveness ◽  
Hiv Infection ◽  
Cost Effective ◽  
On Demand ◽  
Life Years ◽  
Lifetime Costs ◽  
Sex With Men ◽  
Exposure Prophylaxis ◽  
Prevention Of Hiv ◽  
Quality Adjusted Life

BACKGROUND: Recent trials report the efficacy of continuous tenofovir-based pre-exposure prophylaxis (PrEP) for prevention of HIV infection. The cost effectiveness of ‘on demand’ PrEP for non-injection drug-using men who have sex with men at high risk of HIV acquisition has not been evaluated.OBJECTIVE: To conduct an economic evaluation of the societal costs of HIV in Canada and evaluate the potential benefits of this PrEP strategy.METHODS: Direct HIV costs comprised outpatient, inpatient and emergency department costs, psychosocial costs and antiretroviral costs. Resource consumption estimates were derived from theCentre Hospitalier de l’Université de MontréalHIV cohort. Estimates of indirect costs included employment rate and work absenteeism. Costs for ‘on demand’ PrEP were modelled after an ongoing clinical trial. Cost-effectiveness analysis compared costs of ‘on demand’ PrEP to prevent one infection with lifetime costs of one HIV infection. Benefits were presented in terms of life-years and quality-adjusted life-years.RESULTS: The average annual direct cost of one HIV infection was $16,109 in the least expensive antiretroviral regimen scenario and $24,056 in the most expensive scenario. The total indirect cost was $11,550 per year. Total costs for the first year of HIV infection ranged from $27,410 to $35,358. Undiscounted lifetime costs ranged from $1,439,984 ($662,295 discounted at 3% and $448,901 at 5%) to $1,482,502 ($690,075 at 3% and $485,806 at 5%). The annual cost of PrEP was $12,001 per participant, and $621,390 per infection prevented. The PrEP strategy was cost-saving in all scenarios for undiscounted and 3% discounting rates. At 5% discounting rates, the strategy is largely cost-effective: according to least and most expensive scenarios, incremental cost-effectiveness ratios ranged from $60,311 to $47,407 per quality-adjusted life-year.CONCLUSION: This ‘on demand’ PrEP strategy ranges from cost-saving to largely cost-effective. The authors believe it represents an important public health strategy for the prevention of HIV transmission.

Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016

2017 ◽  
Vol 35 (6) ◽  
pp. 377-383 ◽  
Author(s):  
Santiago Moreno ◽  
Antonio Antela ◽  
Felipe García ◽  
Julia del Amo ◽  
Vicente Boix ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Executive Summary ◽  
Exposure Prophylaxis ◽  
Prevention Of Hiv
Sign in / Sign up

Export Citation Format

Share Document